Abstract Details

Title Efficacy and Safety of FcRn Inhibitors in Adults with Generalized Myasthenia Gravis: A Systematic Review and Meta-analysis

Topic Autoimmune Neurology

Presentation(s) P1 - Poster Session 1 (12:00 PM-1:00 PM)

Poster/Presentation
Number 1-060

Objective To evaluate the efficacy and safety of FcRn inhibitors compared with placebo or standard therapy in adults with generalized myasthenia gravis.

Background Generalized myasthenia gravis is an antibody-mediated autoimmune disorder
characterized by fluctuating skeletal muscle weakness. Current therapies may be limited by inadequate response or adverse effects. FcRn inhibitors are novel agents that reduce
pathogenic IgG by blocking neonatal Fc receptor–mediated recycling.

Design/Methods A systematic search of Embase, Cochrane, MEDLINE, and ClinicalTrials.gov was conducted for studies published up to April 2026. Randomized controlled trials and observational studies involving adults with generalized myasthenia gravis treated with FcRn inhibitors versus placebo or standard therapy were included. Outcomes included changes in MG-ADL and QMG scores, as well as safety endpoints. Risk of bias was assessed using RoB 2 and ROBINS-I. Random-effects meta-analysis was performed using R (version 4.5.3).

Results Of 712 identified studies, five were included (4 RCTs, 1 observational; N=581). Pooled analysis showed no statistically significant difference in MG-ADL scores (MD -0.94, 95% CI -2.45 to 0.57; p=0.22; I²=91%) or QMG scores (MD -1.74, 95% CI -7.27 to 3.79; p=0.31; I²=90%). However, both outcomes demonstrated a consistent trend favoring FcRn inhibitors, with substantial heterogeneity. Safety outcomes suggested that FcRn inhibitors were well tolerated, with no significant safety concerns.

Conclusions FcRn inhibitors were well tolerated and showed a trend toward clinical improvement,
although results were not statistically significant and were limited by high heterogeneity
and small sample size. Larger randomized controlled trials are needed to confirm their
efficacy in generalized myasthenia gravis.

Authors/Disclosures
Maurya D. Patel, MBBS PRESENTER	Dr. Patel has nothing to disclose.
NagaVenkata Priya Sri Harshitha Somarouthu	Miss Somarouthu has nothing to disclose.
Farheen Kooliyattayil, MBBS	Dr. Kooliyattayil has nothing to disclose.
Caleb Karani, MBBS	Mr. Karani has nothing to disclose.
Berra Nuran Baloglu, Medical Student	Ms. Baloglu has nothing to disclose.
Mehwish Shoaib (Motilal Nehru Medical College)	Miss Shoaib has nothing to disclose.
Vindhya S. Chavali, MD, MBBS	Ms. Chavali has nothing to disclose.

��ɫ��

��ɫ��